VIP会员
(1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并咪唑-2-基]-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯 基本信息
MSDS 用途与合成方法 (1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并咪唑-2-基]-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯价格(试剂级) 上下游产品信息
| 中文名称 | (1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并咪唑-2-基]-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯 |
|---|---|
| 中文同义词 | (1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并咪唑-2-基]-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯;1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并咪唑-2-基]-2-氮;2-[(1R,3S,4S)-2-BOC-2-氮杂双环[2.2.1]庚烷-3-基]-1H-苯并咪唑-6-硼酸频哪醇酯;(1R,3S,4S)-2-(叔丁氧羰基)- 3-(6-(硼酸频哪醇酯)-1H-苯并[D]咪唑-2-基)-2-氮杂双环[2.2.1]庚烷 1256387-87-7;雷迪帕韦中间体1;(1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并[D]咪唑-2-基]-2-氮杂双环-[2.2.1]-庚烷-2-羧酸叔丁酯;雷迪帕韦中间体09;(1R,3S,4S)-3-(6-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)-1H-苯并[D]咪唑-2-基)基)-2-氮杂二环[2.2.1]庚烷-2-羧酸叔丁酯 |
| 英文名称 | ledipasvir interMediate |
| 英文同义词 | Identification Name (1R,3S,4S)-3-[6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester;tert-butyl (1R,3S,4S)-3-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate;(1R,3S,4S)-2-tert-Butyl-3-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-benzo[d]imidazol-2-yl);(1R,3S,4S)-tert-butyl 3-(6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]iMidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate;Identification Name (1R,3S,4S)-3-[6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-;2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-[6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-benziMidazol-2-yl]-, 1,1-diMethylethyl ester, (1R,3S,4S)-;(1R,3S,4S)-3-[6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester;(1R,3S,4S)-2-tert-butyl-3-(6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[D]iMidazol-2-yl)-2-azabicyclo[2.2.1]hept |
| CAS号 | 1256387-87-7 |
| 分子式 | C24H34BN3O4 |
| 分子量 | 439.36 |
| EINECS号 | 1592732-453-0 |
| 相关类别 | 雷迪帕韦中间体;医药中间体;雷迪中间体;原料 |
| Mol文件 | 1256387-87-7.mol |
| 结构式 | ![(1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并咪唑-2-基]-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯 结构式](https://yunshiji.oss-cn-shenzhen.aliyuncs.com/202410/29/1759597018800000199.gif) |
(1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并咪唑-2-基]-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯 性质
| 沸点 | 613.5±35.0 °C(Predicted) |
|---|---|
| 密度 | 1.21±0.1 g/cm3(Predicted) |
| 储存条件 | under inert gas (nitrogen or Argon) at 2-8°C |
| 酸度系数(pKa) | 12.16±0.10(Predicted) |
(1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并咪唑-2-基]-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯 用途与合成方法
安全信息
MSDS信息
(1R,3S,4S)-3-[6-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-苯并咪唑-2-基]-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/08/19 | XW02125638787704 | 雷迪帕韦中间体 (1R,3S,4S)-tert-Butyl 3-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate | 5g | 660元 | |
| 2024/08/19 | XW02125638787703 | 雷迪帕韦中间体 (1R,3S,4S)-tert-Butyl 3-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate | 1g | 198元 |
粤公网安备44196802000105号
400-6226-992